Kunwei raises approximately $59.8M for transcranial ultrasound

Kunwei sells desktop and portable ultrasound systems to hospitals, with newer products meant to help neurology, neurosurgery, intensive-care and emergency teams see brain structures and blood flow through an adult skull. China Star Market Daily reported that the Shenzhen company completed an approximately $59.8 million B+ round from XVC, Sequoia China, Sherpa and Tencent. XVC and Sequoia China were new investors, while Sherpa and Tencent followed on. The money is earmarked for product development, clinical validation and market expansion. Figures are in US dollars, converted at October 9, 2026 reference rates.

That clinical target is unusually difficult for ultrasound. Bone weakens, scatters and distorts sound waves, while lowering frequency to reach deeper tissue ordinarily sacrifices image detail. Kunwei’s kOS platform coordinates the probe, signal capture, beam synthesis and image reconstruction, using computation to rebuild pictures from echoes disrupted by the skull.

The company says its approach improves views of brain structures and blood flow in adults, and it is working with hospitals on early clinical applications. The important gap is clinical, not merely technical: the report describes early research rather than proof that improved images produce better diagnoses or treatment decisions across different patients and hospitals.

Kunwei first applied its imaging stack to conventional ultrasound. Its Rocvue T7 series received a Chinese Class II medical-device registration in 2024, while the portable WE8 was listed in Europe as a Class IIa ultrasound scanner. Those registrations cover ultrasound scanning; they don’t by themselves establish every claim being explored for transcranial use.

Commercially, Kunwei combines probes, transmit-and-receive hardware, computing modules and imaging software into finished devices sold through hospital procurement and distributors. China Star Market Daily said equipment sales are the current business model and that Kunwei hasn’t disclosed separate licensing or fees for kOS. Its intended distinction is adult brain-structure and blood-flow imaging inside a clinical ultrasound system that can serve several departments.

Established ultrasound vendors enter hospital tenders with broader product lines, installed bases and service networks. Kunwei’s technical case therefore has to become a procurement case: hospitals must decide that transcranial capability warrants buying and deploying the system, rather than treating it as another feature on a general-purpose scanner.